N/A N=84 A Pilot Study to Assess the Amnesic Properties of Dexmedetomidine in Pediatric Patients
Memory · Dexmedetomidine
Primary: Sedation Threshold — 26.8; 38.9 Number of Memory Cards
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=248 Dissemination of the Look Ahead Weight Management Treatment in the Military
Overweight · Obesity
Primary: Percent Weight Loss (Baseline to 12 Months) — 2.1; 0.0 percent weight loss — p=<0.001
N/A N=40 Creatine, Carnitine and Carnosine in Vegetarians
Dietary Modification
Primary: Fasted Plasma Beta-alanine Concentration — 3.37; 5.19; 4.56; 3.76 µM
Phase 1 N=24 Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) — 1634 ng/mL
Phase 3 N=405 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Liver Cancer · Anxiety Disorder · Depression
Primary: Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G) — 3.35; 0.12 units on a scale — p=0.104
Phase 3 N=404 A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
Parkinson's Disease
Primary: Change From Baseline in Mean Daily OFF-time During Treatment Period — -0.51; -1.11; -1.35 hours per day — p=0.0006
Phase 2 N=40 Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
Acne Vulgaris
Primary: Total Lesion Count (Inflammatory and Non-inflammatory) — 23.57; 32.90 Lesions — p=<.001
Phase 3 N=198 A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
Parkinson's Disease
Primary: Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 51; 91 Participants
Phase 4 N=72 LIPT - Liraglutide in Polycystic Ovary Syndrome
Polycystic Ovary Syndrome · Cardiovascular Disease
Primary: Change in Endogenous Thrombin Potential (ETP) — -56.7; -8.2 nMolar x minutes
Phase 1 N=18 Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study
Healthy
Primary: Area Under Plasma Concentration-time at Time t (AUC0-t) — 915; 909 h*μg/mL
N/A N=240 Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Mean Number of Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations and Emergency Department (ED) Visits Per Patient Within Each Study Arm — 0.72; 1.40…
Phase 2 N=39 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
Thrombocytopenia Associated With Chronic Liver Disease
Primary: Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4 — 9.1; 28.6; 63.6; 40.0…
Phase 4 N=61 A Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks
Volume Restoration and Shaping of the Buttocks
Primary: Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 6 — 80.4 percentage of participants
N/A N=78 Overnight Closed Loop Study in U.S.
Type 1 Diabetes
Primary: Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform) — 69.3 percentage of time
Phase 2 N=65 Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints
HIV
Primary: Mean Percent Change From Baseline for D-dimer (ng/mL) to the Average of Weeks 8 and 12 — -10.8; -8.5 percent